247 related articles for article (PubMed ID: 34922436)
1. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
[TBL] [Abstract][Full Text] [Related]
2. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.
Spierings ELH; Kärppä M; Ning X; Cohen JM; Campos VR; Yang R; Reuter U
J Headache Pain; 2021 Apr; 22(1):26. PubMed ID: 33863272
[TBL] [Abstract][Full Text] [Related]
4. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
7. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Igarashi H; Hirata K; Takeshima T; Ning X; Shima T; Ishida M; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1092-1101. PubMed ID: 34324700
[TBL] [Abstract][Full Text] [Related]
9. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
10. Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
Pazdera L; Cohen JM; Ning X; Campos VR; Yang R; Pozo-Rosich P
Cephalalgia; 2021 Sep; 41(10):1075-1088. PubMed ID: 33990144
[TBL] [Abstract][Full Text] [Related]
11. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Lampl C; Rapoport AM; Cohen JM; Barash S; Ramirez Campos V; Seminerio MJ; Ning X; Silberstein SD
Eur J Neurol; 2022 Jul; 29(7):2129-2137. PubMed ID: 35302681
[TBL] [Abstract][Full Text] [Related]
14. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
15. Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Ashina M; Mitsikostas DD; Ramirez Campos V; Barash S; Ning X; Diener HC
Headache; 2023; 63(10):1351-1358. PubMed ID: 37955395
[TBL] [Abstract][Full Text] [Related]
16. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.
Silberstein SD; Cohen JM; Seminerio MJ; Yang R; Ashina S; Katsarava Z
J Headache Pain; 2020 Sep; 21(1):114. PubMed ID: 32958075
[TBL] [Abstract][Full Text] [Related]
17. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
Winner PK; Spierings ELH; Yeung PP; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Headache; 2019 Nov; 59(10):1743-1752. PubMed ID: 31675102
[TBL] [Abstract][Full Text] [Related]
18. Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Tatsuoka Y; Imai N; Ning X; Ishida M; Nagano K; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1102-1111. PubMed ID: 34323290
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study.
Sakai F; Suzuki N; Ning X; Ishida M; Usuki C; Iba K; Isogai Y; Koga N
Drug Saf; 2021 Dec; 44(12):1355-1364. PubMed ID: 34687446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
